Literature DB >> 18691974

DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk.

Wei Zou1, Jennifer L Reeve, Yuli Liu, Steven L Teitelbaum, F Patrick Ross.   

Abstract

We examined the mechanism by which M-CSF regulates the cytoskeleton and function of the osteoclast, the exclusive bone resorptive cell. We show that binding of M-CSF to its receptor c-Fms generates a signaling complex comprising phosphorylated DAP12, an adaptor containing an immunoreceptor tyrosine-based activation motif (ITAM) and the nonreceptor tyrosine kinase Syk. c-Fms tyrosine 559, the exclusive binding site of c-Src, is necessary for regulation of DAP12/Syk signaling. Deletion of either of these molecules yields osteoclasts that fail to reorganize their cytoskeleton. Retroviral transduction of null precursors with wild-type or mutant DAP12 or Syk reveals that the SH2 domain of Syk and the ITAM tyrosine residues and transmembrane domain of DAP12 mediate M-CSF signaling. Our data provide genetic and biochemical evidence that uncovers an epistatic signaling pathway linking the receptor tyrosine kinase c-Fms to the immune adaptor DAP12 and the cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691974      PMCID: PMC2584874          DOI: 10.1016/j.molcel.2008.06.023

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  43 in total

Review 1.  Intracellular signaling by the killer immunoglobulin-like receptors and Ly49.

Authors:  D W McVicar; D N Burshtyn
Journal:  Sci STKE       Date:  2001-03-27

2.  Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts.

Authors:  S Takeshita; K Kaji; A Kudo
Journal:  J Bone Miner Res       Date:  2000-08       Impact factor: 6.741

3.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 4.  The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function.

Authors:  L L Lanier; A B Bakker
Journal:  Immunol Today       Date:  2000-12

5.  Inhibition of beta 2 integrin receptor and Syk kinase signaling in monocytes by the Src family kinase Fgr.

Authors:  C M Vines; J W Potter; Y Xu; R L Geahlen; P S Costello; V L Tybulewicz; C A Lowell; P W Chang; H D Gresham; C L Willman
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

Review 6.  Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization.

Authors:  Julia C Feldner; Burkhard H Brandt
Journal:  Exp Cell Res       Date:  2002-01-15       Impact factor: 3.905

7.  Syk is required for integrin signaling in neutrophils.

Authors:  Attila Mócsai; Meijuan Zhou; Fanying Meng; Victor L Tybulewicz; Clifford A Lowell
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

8.  Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function.

Authors:  Xu Feng; Sunao Takeshita; Noriyuki Namba; Shi Wei; Steven L Teitelbaum; F Patrick Ross
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

Review 9.  CD200 and membrane protein interactions in the control of myeloid cells.

Authors:  A Neil Barclay; Gavin J Wright; Gary Brooke; Marion H Brown
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

10.  Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton.

Authors:  Achim Obergfell; Koji Eto; Attila Mocsai; Charito Buensuceso; Sheri L Moores; Joan S Brugge; Clifford A Lowell; Sanford J Shattil
Journal:  J Cell Biol       Date:  2002-04-08       Impact factor: 10.539

View more
  56 in total

1.  Cytoskeletal dysfunction dominates in DAP12-deficient osteoclasts.

Authors:  Wei Zou; Tingting Zhu; Clarissa S Craft; Thomas J Broekelmann; Robert P Mecham; Steven L Teitelbaum
Journal:  J Cell Sci       Date:  2010-09-01       Impact factor: 5.285

Review 2.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

3.  TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis.

Authors:  Karel Otero; Masahiro Shinohara; Haibo Zhao; Marina Cella; Susan Gilfillan; Angela Colucci; Roberta Faccio; F Patrick Ross; Steve L Teitelbaum; Hiroshi Takayanagi; Marco Colonna
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

4.  CSF-1R, DAP12 and beta-catenin: a ménage à trois.

Authors:  Daniel W McVicar; Giorgio Trinchieri
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

Review 5.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

Review 6.  Cross-regulation of signaling by ITAM-associated receptors.

Authors:  Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

7.  Zap70 inhibits Syk-mediated osteoclast function.

Authors:  Wei Zou; Monica Croke; Tomohiro Fukunaga; Thomas J Broekelmann; Robert P Mecham; Steven L Teitelbaum
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

Review 8.  The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells.

Authors:  Jessica A Hamerman; Minjian Ni; Justin R Killebrew; Ching-Liang Chu; Clifford A Lowell
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

Review 9.  Osteoclast motility: putting the brakes on bone resorption.

Authors:  Deborah V Novack; Roberta Faccio
Journal:  Ageing Res Rev       Date:  2009-09-27       Impact factor: 10.895

Review 10.  A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.

Authors:  Mary Beth Humphrey; Mary C Nakamura
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.